Global Human Papillomavirus (HPV) Therapeutics Market Driven by Rising Prevalence of HPV Infections

Human papillomavirus (HPV) and cytomegalovirus (CMV) are viral pathogens affecting individuals of all ages. HPV causes serious sexually transmitted diseases (STDs), while CMV is an opportunistic pathogen affecting immunocompromised individuals such as HIV patients. The global market for HPV and CMV therapeutics is expected to experience a surge due to various macro and micro economic factors.

More than 100 strains of HPV have been identified till date, of which certain types are known to cause warts or papillomas that progress to benign or malignant cancers. HPV infections are common in adolescents and young adults with highest prevalence in adolescent females. According to CDC, in 2012, an estimated 20 million persons were infected that year in the U.S., and an estimated 6.2 million new HPV infections were expected to occur annually. The human papillomavirus therapeutics market includes immunomodulators, keratolytic agents, anti-neoplastic agents and sinecatechins. Immunomodulators account for the largest share of the global HPV therapeutics market, while the sinecatechins segment is expected to be the fastest growing market segment.

Read More:

0 rating(s) (0 ø)
Views: 63

All rights reserved

• This document may not be used, copied nor changed without explicit consent of the author.
Copyright Icon
The maximum length of a comment is 1000 characters.
The maximum length of an alias is 30 characters.
Please enter a comment.
Please insert a valid comment!